Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LIPO
- Price
- 1.65
- Stock movement down
- -0.71 (-30.08%)
- Company name
- Lipella Pharmaceuticals Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 7.62M
- Ent value
- 707.46M
- Price/Sales
- 0.06
- Price/Book
- 0.01
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -67.92%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LIPO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.06 |
| Price to Book | 0.01 |
| EV to Sales | 5.17 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.62M |
| EPS (TTM) | -2130.82 |
| FCF per share (TTM) | -2658.75 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 136.78M |
| Gross profit (TTM) | 135.07M |
| Operating income (TTM) | -4.36M |
| Net income (TTM) | -2.38B |
| EPS (TTM) | -2.13K |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.75% |
| Operating margin (TTM) | -3.19% |
| Profit margin (TTM) | -1743.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.35M |
| Net receivables | 31.08K |
| Total current assets | 2.08B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 209.85K |
| Total assets | 2.16B |
| Accounts payable | 459.45K |
| Short/Current long term debt | 70.83K |
| Total current liabilities | 701.19K |
| Total liabilities | 701.19M |
| Shareholder's equity | 1.46B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.96B |
| Capital expenditures (TTM) | 14.42M |
| Free cash flow (TTM) | -2.98B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -163.45% |
| Return on Assets | -110.40% |
| Return on Invested Capital | -163.45% |
| Cash Return on Invested Capital | -203.94% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.76 |
| Daily high | 2.36 |
| Daily low | 1.61 |
| Daily Volume | 190K |
| All-time high | 37.68 |
| 1y analyst estimate | 10.00 |
| Beta | -0.09 |
| EPS (TTM) | -2130.82 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 3 Sep 2025 |
Downside potential
Loading...
Downside potential data
| LIPO | S&P500 | |
| Current price drop from All-time high | -95.62% | -3.04% |
| Highest price drop | -95.62% | -56.47% |
| Date of highest drop | 20 Jun 2025 | 9 Mar 2009 |
| Avg drop from high | -76.20% | -11.04% |
| Avg time to new high | 314 days | 12 days |
| Max time to new high | 626 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
7.62M
Marketcap category
Small-cap
Description
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner